Sequenta expands reach of ultrasensitive cancer Dx test

Sequenta is marketing its gene sequencing-based cancer test for two new indications, making good on its promise to expand the sales and clinical validation of the diagnostic after raising $20 million in new venture money in July 2013. The South San Francisco diagnostics outfit said its ClonoSIGHT test is now available for patients with multiple myeloma and diffuse large B-cell lymphoma. Sequenta first used the test for acute lymphoblastic leukemia, chronic lymphocytic leukemia and mantle cell lymphoma patients when it initially launched in February 2013. ClonoSIGHT works on Sequenta's LymphoSIGHT platform to spot minute levels of leukemia and lymphoma cells remaining in patients' blood after treatment. With a turnaround time of about 7 days, the test works faster than radiation-based imaging and spots residual cancer cells with greater sensitivity than current standards of care allow. Item